All News

We’re now entering the fourth decade of HIV/AIDS awareness. Last year marked the 30th anniversary of the earliest report (on June 5, 1981) of what is now known as AIDS (acquired immune deficiency syndrome).

With National HIV Testing Day recently behind us and the 19th International AIDS conference happening later in July in Washington, DC, I would like to share some recent HIV/AIDS statistical, research, and policy highlights.

The FDA approved the mTOR inhibitor everolimus (Afinitor) last week for use in postmenopausal women with HER2-negative, hormone-receptor-positive advanced breast cancer patients.

A new target of melanoma tumors has been identified that may be promising as part of a novel combination therapy for melanoma. In a study published in Nature Medicine, researchers have identified that more than half of melanoma cases, both early and late-stage, may have higher levels of MDM4, a p53-interacting protein.

CancerNetwork speaks with two practicing oncologists about how the recent Supreme Court decision to uphold the Affordable Care Act will affect oncology practices and patients.

A new study finds higher levels of vitamin E consumption could stave off liver cancer. The association held up for those who had a family history of liver disease and those who self-reported liver disease.

ICD-10 is a massive undertaking that expands our current 13,000 codes to 68,000 codes. It will impact nearly all business processes in a physician's practice: verification of eligibility, pre-authorization, clinical documentation, research activities, public health reporting, quality reporting, and claim submission.

How should oncologists advise patients about the best surgical approach to use to treat their prostate cancer? Quite simply, it is the surgeon, not the approach. The self-fulfilling prophecy about surgery is that the best surgeons tend to do the most surgeries, so an easy metric is volume.

CancerNetwork speaks with Dr. Sara Hurvitz, director of the breast cancer program at the University of California in Los Angeles. Dr. Hurvitz is actively involved in translational phase I/II breast cancer clinical trials as well as in research to better define distinct types of breast tumors to better design novel targeted therapies.

For oncologists, the impact of the Supreme Court's decision on the Affordable Care Act will likely mean that their patients will no longer be in danger of losing insurance or being denied insurance because of cancer.

For independent physician practices, the realities of overhead expenses, time available for patient care, and regulatory requirements can only be assessed when the specific requirements for reporting and reimbursement are clear.

As with any legislation, there are both positive and negative aspects. Specific to oncology, one of the greatest impacts of the ACA will be the move to a bundled payment for a treatment of a disease.

This will have a significant impact on medicine and on the care we will be able to deliver. It has life and death implications. The patients of America, who have enjoyed the best healthcare in the world, have lost.

How will we deal with patients and families who, given their tremendous access to information, learn about and demand expensive (and up until now reasonable) treatments once we have recast them as too expensive to justify their marginal benefits? Are we prepared to engage in such discussions directly?

I think it is a real shame that inside the Beltway, both sides of the political arena have had neither the wisdom nor the courage to recognize and address the fact that medicolegal drivers will continue to push costs upward until someone takes the lead in tackling this issue.

My thought is that it is good to move forward. No doubt there will be needed changes, but the status quo is broken.

Researchers at the Roswell Park Cancer Institute believe that cancer studies should take into account the tobacco and smoking habits of participants-something that rarely happens. Whether a trial participant uses tobacco products can affect cancer treatment, say the group of investigators.

Learn how to help cancer patients and survivors ease into an exercise routine to promote overall wellness and combat fatigue.

As practicing doctors and a practicing nutritionist in a large pediatric oncology program, we applaud Nicole Fox and Alison Freifeld for questioning the utility of the neutropenic diet.

The article by Fox and Freifeld presents a comprehensive history of the rationale for the neutropenic diet, along with important studies of this diet.

Through our sister site, Physicians Practice, we are able to provide you with news and information you can use to help run your private medical practice from experts covering everything from health IT innovations to small rewards for your office staff. But now we want to hear from our other experts - you. Take our brief editorial survey to tell us what you want to read in the coming year both in print and online. We've provided some topics, you just tell us how interested you are in these ideas. By completing the survey, you'll have the chance to enter to win a $500 Visa gift card. The survey will run through July 27th. No purchase is necessary. Void where prohibited. Visa is not a particular in or sponsor of this Sweepstakes. See official rules for full details.

Review of the pathophysiology of foodborne illness and pertinent studies about the neutropenic diet lead to the conclusion that there is no clear benefit from the longstanding dietary restrictions that may be imposed during neutropenia. Instead, we propose adoption of standard safe food handling methods to allow for a more liberalized diet in the neutropenic patient.

The underlying cost debate surrounding the issue of whether or not to recommend prostate cancer screening is based on the idea that if you use healthcare resources in one area, they’re being diverted from another area by nature of their being a limited pool of funding.

CancerNetwork and the journal ONCOLOGY present exclusive coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Visit one of our topic-specific ASCO pages or follow the stories below to catch some of the most important information to come out of this year's event.

CancerNetwork and the journal ONCOLOGY present exclusive hematology coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Check out the stories below for write-ups of the most important information to come out of this year's event.

CancerNetwork and the journal ONCOLOGY present exclusive melanoma coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Check out the stories below for write-ups of the most important information to come out of this year's event.

CancerNetwork and the journal ONCOLOGY present exclusive breast cancer coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Check out the stories below for write-ups of the most important information to come out of this year's event.

CancerNetwork and the journal ONCOLOGY present exclusive lung cancer coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Check out the stories below for write-ups of the most important information to come out of this year's event.

The debate over screening for lung cancer continues. While there have been many advances in treatment for late-stage disease, screening and prevention are likely the most cost effective and best approaches to preventing lung cancer deaths.

I confess that I have never taken chemotherapy. Strictly speaking this disqualifies me from commenting any further, so I should sign off now. If, however, you don’t mind hearing from one who has administered chemotherapy by the thousands and can bear witness to its effects, then please read on.